大剂量阿托伐他汀治疗急性冠脉综合征合并糖尿病的近期疗效

Short-term clinical efficacy of high dose of atorvastain in treatment of patients with acute coronary syndrome and diabetes mellitus

目的观察大剂量阿托伐他汀治疗对急性冠脉综合征(ACS)合并糖尿病患者的近期疗效。方法将100例ACS合并糖尿病患者随机均分为阿托伐他汀10mg/d组(A组)和阿托伐他汀40mg/d组(B组),采用流式细胞术检测外周血NF-κB活性,酶联免疫吸附法和乳胶增强投射免疫比浊法分别检测IL-6和高敏C反应蛋白(hsCRP)水平,统计两组治疗期间心血管事件发生率。结果两组治疗后,外周血NF-κB活性以及IL-6、hsCRP水平均低于治疗前(P<0.05或P<0.01),B组低于A组(P<0.05或P<0.01)。B组近期心血管事件发生率低于A组(10%vs.18%)(P<0.05)。结论大剂量阿托伐他汀能明显抑制ACS合并糖尿病患者体内炎性反应,减少近期心血管事件的发生。

Objective To investigate the short-term clinical efficacy of high dose of atorvastain in the treatment of patients with acute coronary syndrome（ACS）and diabetes mellitus（DM）.Methods A total of 100 patients with ACS and DM was equally randomized into two groups of A（treated with atorvastain 10mg/d）and B（treated with atorvastain 40mg/d）.The activity of NF-κB in peripheral blood was measured by flow cytometry.The levels of IL-6 and high sensitive C-reactive protein（hsCRP） were detected by ELISA and latex-enhanced immunoturbidimetry,respectively.The incidence of cardiovascular events was calculated during the treatment.Results The activity of NF-κB and levels of IL-6 and hsCRP after treatment were lower than those before treatment in both groups（P〈0.05 or P〈0.01）,which were lower in group B than those in group A（P〈0.05 or P〈0.01）.The incidence of short-term cardiovascular events in group B was lower than that in group A（10% vs.18%）（P〈0.05）.Conclusion Atorvastatin in high dose may effectively inhibit inflammatory response and reduce the short-term cardiovascular events in the patients with ACS and DM.